Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
78 results about "Fibroblast growth factor receptor 1" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Fibroblast growth factor receptor 1 (FGFR1), also known as basic fibroblast growth factor receptor 1, fms-related tyrosine kinase-2 / Pfeiffer syndrome, and CD331, is a receptor tyrosine kinase whose ligands are specific members of the fibroblast growth factor family. FGFR1 has been shown to be associated with Pfeiffer syndrome.
Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
InactiveUS20070248605A1Microbiological testing/measurementImmunoglobulins against growth factorsAbnormal tissue growthAntibody
A composition is provided that contains a polypeptide and a modulator or a cell comprising the polypeptide and a modulator, where the modulator specifically interferes with the activity of the polypeptide, and the polypeptide is either FGFR3 or FGFR4, inclusive of all polymorphic forms and variants thereof. The modulator can be an antibody or active fragments thereof, a small molecule drug, an RNAi molecule, an antisense molecule or a ribozyme. A method of treatment of tumors in a subject is also provided where an antagonist of FGFR3 or FGFR4 is administered to the subject.
Owner:FIVE PRIME THERAPEUTICS
Muteins of fibroblast growth factor 21
ActiveUS7622445B2Reduce sensitivityReduced O-glycosylationPeptide/protein ingredientsMetabolism disorderMutated proteinNucleic acid sequence
Owner:ELI LILLY & CO
Muteins of fibroblast growth factor 21
Owner:ELI LILLY & CO
Muteins of fibroblast growth factor 21
InactiveUS7655627B2Reduced deamidationReduce capacityPeptide/protein ingredientsMetabolism disorderADAMTS ProteinsWild type
The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced deamidation compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.
Owner:ELI LILLY & CO
Fibroblast growth factor-21-Fc fusion proteins
ActiveUS9006400B2Easy to controlImproved profilePeptide/protein ingredientsAntibody mimetics/scaffoldsProtein CFibroblast growth factor receptor 1
Owner:NOVARTIS AG
Fibroblast growth factor-like polypeptides
The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.
Owner:AMGEN INC
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
ActiveUS20100047251A1Strong specificityHigh affinityImmunoglobulins against growth factorsAntibody ingredientsFGF ReceptorReceptor activation
The present invention is related to antibodies with binding affinity to fibroblast growth factor receptor 2 (FGFR2) optionally with binding affinity to other FGF receptors, which block both ligand-dependent and constitutive ligand independent receptor activation. Specifically, the present invention relates to antibodies with high affinity to more than one FGF receptor subtype, and fragments thereof, useful in treating disorders including cell proliferative diseases.
Owner:FIBRON
Dual function proteins for treating metabolic disorders
ActiveUS20130129724A1Easy to controlImproved profilePeptide/protein ingredientsAntibody mimetics/scaffoldsFibre cellMetabolic profile
The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.
Owner:NOVARTIS AG
Remodeling and glycopegylation of fibroblast growth factor (FGF)
ActiveUS20120172300A1Cost effectiveImprove pharmacokineticsSenses disorderNervous disorderFibre cellMutant
Owner:89BIO LTD
Mutant polypeptides of fibroblast growth factor 1
ActiveUS7595296B1Good effectFacilitated DiffusionPeptide/protein ingredientsDepsipeptidesWild typeX-ray
The β-trefoil protein human fibroblast growth factor-1 (FGF-1) is made up of a six-stranded anti-parallel β-barrel closed off on one end by three β-hairpins, thus exhibiting a three-fold axis of structural symmetry. The N- and C-termini β-strands hydrogen bond to each other and are postulated from both NMR and X-ray structure data to represent a structurally-weakened region of the β-barrel. Val mutations within the N- and C-termini β-strands are shown to stabilize the structure and to increase van der Waals contacts by filling local cavities present within this region. Mutations that increase van der Waals contacts between both the N- and C-termini β-strands are generally associated with significant reductions in the unfolding kinetics, and also increase the cooperativity of unfolding. Surprisingly, several mutant polypeptides herein disclosed greatly exceed the wild-type polypeptide in ability to stimulate human fibroblasts to proliferate.
Owner:FLORIDA STATE UNIV RES FOUND INC
Fibroblast growth factor 21 mutations
InactiveUS9023791B2Good biological propertiesPeptide/protein ingredientsAntibody mimetics/scaffoldsBiologyFGF21
Owner:NOVARTIS AG
Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
ActiveUS9550820B2Peptide/protein ingredientsAntibody mimetics/scaffoldsFibroblast growth factor 23C-terminus
Owner:NEW YORK UNIV
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
The present invention is related to antibodies with binding affinity to fibroblast growth factor receptor 2 (FGFR2) optionally with binding affinity to other FGF receptors, which block both ligand-dependent and constitutive ligand independent receptor activation. Specifically, the present invention relates to antibodies with high affinity to more than one FGF receptor subtype, and fragments thereof, useful in treating disorders including cell proliferative diseases.
Owner:FIBRON
Fgfr1 extracellular domain combination therapies
InactiveUS20120237511A1Inhibit tumor cell growthOrganic active ingredientsHeavy metal active ingredientsCarboplatinDocetaxel
Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and / or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and / or an FGFR1 ECD fusion molecule and / or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and / or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.
Owner:FIVE PRIME THERAPEUTICS
Hair growth methods using fgfr4 extracellular domains
The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 4 (FGFR4) extracellular domain (ECD), including native FGFR4 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.
Owner:FIVE PRIME THERAPEUTICS
Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to fgf21
ActiveUS20130035373A1Modulate its functionOrganic active ingredientsGenetic material ingredientsDiseasePolynucleotide
The present invention relates to antisense oligonucleotides that modulate the expression of and / or function of Fibroblast growth factor 21 (FGF21), in particular, by targeting natural antisense polynucleotides of Fibroblast growth factor 21 (FGF21). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of FGF21.
Owner:CURNA INC
Dual function proteins for treating metabolic disorders
ActiveUS20170166621A1Easy to controlImproved profilePeptide/protein ingredientsAntibody mimetics/scaffoldsFibre cellMetabolic profile
The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.
Owner:NOVARTIS AG
Bitarget fibroblast growth factor acceptor and transgene carrier of integrated element
InactiveCN1757738AGrowth inhibitionLow transfection efficiencyGenetic material ingredientsFermentationAbnormal tissue growthDisease
A transgenic carrier with deal targets (fibroblast growth factor receptor and integrant) is composed of the polypeptide CR16 specifically linked with alkaline fibroblast growth factor receptor, the polypeptide CP9 specifically linked with integrant, and the transgenic non-virus carrier system of CR16 / CP9 / cationic polymer PEI / exogenous DNA. Said carrier can effectively introduce the exogenous DNA to the tumor cell line and tumor tissue with high expression of FGFRs, so suppressing the growth of tumor. It can be used to preparation of the medicine for treating tumor and other diseases.
Owner:ZHEJIANG UNIV
Therapeutic agent for cancer, and method for treatment of cancer
InactiveUS20110129524A1High expressionImprove aimingBiocidePeptide/protein ingredientsTherapeutic effectCancer therapy
[Problems] To provide a technique which enables an effective antibody therapy for cancer which targets for FGFR1 without the need of using any effective antibody having high specificity and a potent cell-killing activity.[Means for Solving Problems] Disclosed are: a therapeutic agent for cancer, which comprises an enhancer of the expression of a fibroblast growth factor receptor-1 and an anti-fibroblast growth factor receptor-1 antibody; and a method for the treatment of cancer using the therapeutic agent.
Owner:THE UNIV OF TOKYO +1
Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
InactiveUS7083791B2Reduce decreaseDecreasing osteopontin gene expressionOrganic active ingredientsBiocideHepatocellular carcinomaAutoimmune disease
Isolated fibroblast growth factor receptor (FGFR5) polypeptides and polynucleotides encoding such polypeptides are provided. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to and agonize or antagonize FGFR5 polypeptide function. Specific binding molecules include antibodies, functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5 and, thus, are effective agents suitable for the treatment of diseases such as osteopontin-mediated autoimmune disease, such as systemic lupus erythematosus, bone disorders including osteoporosis and osteopetrosis, and cancers, including cellular carcinomas such as hepatocellular carcinomas.
Owner:GENESIS RES & DEV
Fusion proteins for treating metabolic disorders
ActiveUS20130079500A1Easy to controlImproved profilePeptide/protein ingredientsAntibody mimetics/scaffoldsFibroblast growth factor 23Metabolic disorder
The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
Owner:NOVARTIS AG
Detection chip for tumor driving gene and application thereof
The invention discloses a detection chip for a tumor driving gene and application thereof. The detection chip for the tumor driving gene comprises an ALK (anaplastic lymphoma kinase) fusion detection agent, an EGFR (epidermal growth factor receptor) fusion detection agent, an RET (reticulocyte) fusion detection agent and an ROS1 (reactive oxygen species 1) fusion detection agent. Proofed by the results of clinical detect, after fusion probes corresponding to the ALK, the EGFR, the RET and the ROS1 are specifically designed, the detection chip has the advantages that the sensitivity is high, and the gene fusion between a particular site area of the ALK, the EGFR, the RET and the ROS1 and fusion segments is specifically detected. The invention further discloses a detection chip for detecting a second sequence group of the gene mutation and a third sequence group of the gene amplification; after detecting once, the gene fusion, gene mutation and gene amplification of the multiple tumor driving genes, such as the ALK, BRAF (aserine / theroninespecific kinases), DDR2 (discordin domain receptor 2), the EGFR, ERBB2 (receptor tyrosine kinase 2), FGFR1 (fibroblast growth factor receptor 1), KRAS (kirstenrat sarcoma viral oncogene), MET (methionine), NRAS, PIK3CA (phosphatidylino-sitol 3-kinases), the RET and the ROS1.
Owner:常州桐树生物科技有限公司
Keratinocyte growth factor-2
InactiveCN1372569AImprove biological activityAntibacterial agentsOrganic active ingredientsBiotechnologySolubility
The present invention relates to various newly identified polynucleotides, polypeptides encoded by such polynucleotides, uses of such polynucleotides and polypeptides, and production of such polynucleotides and polypeptides. More specifically, the polypeptide of the present invention is keratinocyte growth factor, sometimes referred to hereinafter as "KGF-2," and formerly referred to as fibroblast growth factor 12 (FGF-12). The present invention also relates to the therapeutic use of KGF-2 for promoting or accelerating wound healing. The present invention also relates to new mutant forms of KGF-2 which show enhanced activity, increased stability, higher yield or better solubility.
Owner:HUMAN GENOME SCI INC
Method for Enhancing the Growth and Fullness of Hair
InactiveUS20130064905A1Extension of timeImprove scalabilityBiocideCosmetic preparationsEyelashHair growth
New fibroblast growth factor receptor 1 (FGFR1) inhibitors have been identified which are useful for promoting the retention and / or growth of keratin fibers, such as hair of the scalp, hair of the face (moustache, beard, etc.), eyebrows, eyelashes, and the like. The FGFR1 inhibitors may be formulated in effective amounts in a variety of cosmetic and personal care products.
Owner:AVON PROD INC
Methods for targeting cells that express fibroblast growth receptor-3 or -2
Fibroblast growth factor-18 (FGF-18) binds with FGF receptors-2 and -3. Compositions comprising an FGF-18 component can be used to target cells that express these receptors. Suitable targets include tumor cells that express constitutively activated forms of FGF receptors-2 and -3. For example, conjugates of FGF-18 and saporin can be used to target tumor cells that express FGF receptors-2 or -3, and to inhibit the proliferation of these cells.
Owner:ZYMOGENETICS INC
Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
ActiveUS20180230197A1Improve survivalPromote sportsPeptide/protein ingredientsSkeletal disorderFibroblast growth factor receptor 2Fibroblast Growth Factor 3 Gene
The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
Owner:PFIZER INC +2
Polytheneimine transgened carrier of targeted fibroblast growth factor receptor
InactiveCN1614027AGrowth inhibitionLow transfection efficiencyGenetic material ingredientsOther foreign material introduction processesAbnormal tissue growthDisease
The invention was involved in the polymine modified vector of fibroblast growth factor receptor, containing peptide YC25 which could specially bind to the alkaline fibroblast growth factor receptor, peptide YC25 / positive ion PEI / exogenous DNA.The exogenous DNA could be effectively introduced to the cancer clone and system of high expression of FGFRs to inhibit the growth of tumor. But there was low effect to the tumor tissue and cell liens without expression of FGFRs, so the vector system was tumor-targeting. The non-virus vector system could transfer the exogenous DNA and its size ranged from tens bp to thousands kb to overcome the limit of the size of exogenous gene. So, it could be used to produce the medicament to cure tumor by combined transfer of multi-gene and also to produce gene drug for other disease.
Owner:ZHEJIANG UNIV
Hair growth methods using FGFR3 extracellular domains
InactiveUS8685931B2Cosmetic preparationsOrganic active ingredientsHair streamsExtracellular Structure
Owner:FIVE PRIME THERAPEUTICS
Mutant growth factors with altered receptor specificities and pharmaceutical composition comprising the same
InactiveUS20090286965A1Regulate a physiological activityCosmetic preparationsNervous disorderMutated proteinReceptor for activated C kinase 1
Disclosed is a mutant protein having an altered fibroblast growth factor receptor specificity, which is produced by deleting one or more amino acid residues from the N-terminus of the amino acid sequence of naturally secreted fibroblast growth factor 18. The protein mutant can be used in a pharmaceutical composition for regulating hair regeneration or growth or a pharmaceutical composition for regulating bone or cartilage formation.
Owner:NAT INST OF ADVANCED IND SCI & TECH
Polypeptide with function of promoting activity of fibroblast growth factor receptor 3 and screening method and application thereof
InactiveCN101619093AHigh activitySmall molecular weightPeptide/protein ingredientsSkeletal disorderDiseaseScreening method
The invention discloses a polypeptide with function of promoting the activity of a fibroblast growth factor receptor 3 (FGFR3) and a screening method and an application thereof. The polypeptide is formed by an amino acid sequence shown as Val-Sel-Pro-Pro-Leu-Thr-Leu-Gly-Gln-Leu-Leu-Ser. The screening method comprises the following steps: incubating a bacteriophage 12 peptide library and an elisa plate coated by the FGFR3 together, washing non-specificity combined bacteriophage, then eluting specificity combined bacteriophage and amplifying to be used as input bacteriophage elutriated in the next turn, repeating the steps for performing elutriations in three turns, extracting DNA singly cloned by the bacteriophage elutriated in the third turn and sequencing, deducting the amino acid sequence of a foreign polypeptide shown on the bacteriophage, synthesizing the polypeptide, detecting the promotion of the polypeptide to the activity of the FGFR3, and obtaining the polypeptide with function of promoting the activity of the FGFR3. The polypeptide can be used for preparing medicine of resisting low FGFR3 function low diseases.
Owner:INST OF FIELD OPERATION SURGERY NO 3 MILITARY MEDICL UNIV PLA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com